chrisvoncsefalvay/vaers-outcomes huggingface dataset:
2 days after vaccine was given, rash was all over body and face swelled. Took to emergency room was given BENADRYL and steroids.
the site where the injection was had a round red mark silver dollar sized, it itched and hurt and it was hot to touch; the site where the injection was had a round red mark silver dollar sized, it itched and hurt and it was hot to touch; the site where the injection was had a round red mark silver dollar sized, it itched and hurt and it was hot to touch; the site where the injection was had a round red mark silver dollar sized, it itched and hurt and it was hot to touch; pus; arm hurt for a few days but it stopped; This is a spontaneous report from a contactable consumer (reporting for herself).  A female patient of an unspecified age received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 MRNA VACCINE), via an unspecified route of administration on 06Jan2021 at a single dose for COVID-19 immunization.  The patient's medical history and concomitant medications were not reported.  In Jan2021, the patient experienced arm hurt for a few days, but it stopped and had puss.  On 15Jan2021, the patient reported that the site where the injection was had a round red mark silver dollar sized, it itched and hurt and it was hot to touch.  Therapeutic measures were taken as a result of the events and included: acetaminophen (TYLENOL).  The outcome of arm hurt for a few days but it stopped was recovered in Jan2021 and of the site where the injection was had a round red mark silver dollar sized, it itched and hurt and it was hot to touch and pus was recovering.    The batch/lot number for the vaccine, BNT162B2, was not provided and will be requested during follow up.
Patient had itching after the 2nd dose Pfizer vaccine was given.  Given diphenhydramine 25 mg PO. Patient had reported hives after first dose.
BURNING UP; HEADACHE; This spontaneous report received from a patient concerned a male of unspecified age. The patient's weight, height, and medical history were not reported. The patient received Covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: Unk) dose was not reported, administered on 02-APR-2021 for prophylactic vaccination. The batch number was not reported and has been requested. No concomitant medications were reported. On 02-APR-2021, the subject experienced burning up. On 02-APR-2021, the subject experienced headache. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of the burning up and headache was not reported. This report was non-serious.
Inflamation and slight soreness at injection site after 8 days. No symptoms prior to day 8.
SUBJECTIVE: He presents today for COPD (Patient states noticed blood with his phelgm for a couple of days. No fever. Short of breath with wheezing at times.  Denies any chest pain or tightness in chest. NO exposure of Covid. He has had vaccine.)
UPON COMPLETION OF ADMINISTRATION 4:45 PM PATIENT STATED SHE WAS FEELING WEAK, AT THAT TIME PT. APPEARED PALE, LOST CONTROL OF LIMBS, AND SHOOK ARMS IN FOLDING POSITION SEIZURE LIKE MOVEMENTS. WASN'T RESPONDING ONSET BEGAN AFTER ADMINISTERING TDAP (ADACEL). HEAD WAS PUT DOWN TO BETWEEN KNEES ICE PACK AND COLD TOWELS WERE PUT ON NECK. COLD WET TOWELS ON FACE. PT GAINED CONSCIOUSNESS. AFTER 1 MINUTE.
reported that doses of GARDASIL9 had been administered following a temperature excursion; This spontaneous report has been received from a health professional, referring to a patient of unknown age and gender. The patient's concurrent conditions, pertinent medical history, concomitant medications, previous drug and/or allergy reactions were not reported.   On 23-AUG-2021, the patient was vaccinated with an improperly stored hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) at a dose of 0.5 milliliter (vaccination scheme, route and anatomical location of administration were not provided; lot # T026167 has been verified to be a valid lot number, and expiration date reported and established upon internal review as 04-DEC-2022) as prophylaxis.   The administered vaccine underwent a temperature excursion below 2 degrees Celsius (°C) of -40.0 °C for a time frame of 15 minutes; and an excursion above 8°C of 9.6 °C for a time frame of 1 hour. No previous temperature excursion was reported. No information about the use of a datalogger was reported.   This is one of several cases, from the same reporter.  combinationproductreport: Yes; brandname: GARDASIL 9 SYRINGE (DEVICE); commondevicename: HPV rL1 6 11 16 18 31 33 45 52 58 VLP vaccine (yeast); productcode: FMF; devicetype: SYRINGE, PISTON (FMF); manufacturername: Merck Sharp & Dohme Corp.; devicelotnumber: T026167; expirationdate: 04-DEC-2022; deviceage and unit: 0 ; malfunction: Unknown; deviceusage: Initial; reasonfornoneval: 81 Other; labeledsingleusedevice: No; mdcpreportability: No; mdcpreprationale: Case information does not meet criteria for reportability
patient started with severe pain at the injection site and progressed into her neck.  At this point the patient's neck is so rigid she can't move it.
First shot was bad; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION COMPLICATION (First shot was bad) in an 82-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced VACCINATION COMPLICATION (First shot was bad). At the time of the report, VACCINATION COMPLICATION (First shot was bad) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medications reported by investigator o No treatment medications provided by the reporter.    This case was linked to MOD-2021-049757, MOD-2021-049757 (Patient Link).
Patient developed urticaria within a few hours of getting the 2nd TRUMENBA vaccine. The urticaria resolved after a few days. The patient then developed an itchy papular rash that looks like folliculitis.
Client received the first dose of Moderna COVID-19 vaccine, he was escorted to the observation area. At the end of his 15-minute observation period, he reported hives on his left forearm. He denied pruritis or any other symptoms. His left forearm had about 10 small red raised hives, separated by an inch. He was directly observed by a nurse for an additional 15 minutes. In that time, the hives subsided nearly completely. The client was advised to closely monitor for any recurring or additional symptoms in the next 1-4 hours. The client was instructed to check in with his medical provider for discussion and further assessment of this mild reaction, in the context of his diagnosed allergy to dust, and determination if he should receive a 2nd dose. In the meantime, he has been added to the list for referral to a hospital for potential vaccination with a 2nd dose.
after injection given  pt became pale heart rate increased flushed nausea and sweats repotes this happens when blood is drawn onsite als notified and transfered care pt states i feel much better color came back family at side
Nausea and violent vomiting for 2 hours.   Upper back and neck pain for 36 hours.  Chills and shaking for 12 hours.  Urine is now colorless instead of yellow-orange.  I have had no treatment.  Urine remains colorless, but other symptoms are almost resolved.
I got Tingling, numbness and hot feeling on my left hand arm my neck to my jaw and my ear down my left leg to my foot for over a week and I?m still experiencing the feeling in my foot all on the left side
Sluggish; Tired; Sneezing; Nasal congestion; Tested positive for Covid; This spontaneous case was reported by a consumer and describes the occurrence of COVID-19 (Tested positive for Covid), SLUGGISHNESS (Sluggish), FATIGUE (Tired), SNEEZING (Sneezing) and NASAL CONGESTION (Nasal congestion) in a 54-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 031L20A) for COVID-19 vaccination.     No Medical History information was reported.    On 02-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 21-Feb-2021, the patient experienced COVID-19 (Tested positive for Covid). On an unknown date, the patient experienced SLUGGISHNESS (Sluggish), FATIGUE (Tired), SNEEZING (Sneezing) and NASAL CONGESTION (Nasal congestion). At the time of the report, COVID-19 (Tested positive for Covid), SLUGGISHNESS (Sluggish), FATIGUE (Tired), SNEEZING (Sneezing) and NASAL CONGESTION (Nasal congestion) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 21-Feb-2021, SARS-CoV-2 test: Positive.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.
Evening of injection, tongue started bothering her with little bumps.  Lower inside lower lip had bumps on it.  Took Benadryl.  During the week Wednesday, left eyelid was swollen, and then before going to bed both were swollen.  Seem to have gotten better.  Went to the doctor and advised to not take the 2nd vaccine.  Has had light headedness and dizziness since the day after the vaccine, still having some symptoms.
On October 24, 2022 LVN administered a 2nd dose flu vaccine to an 8 month old only 2 weeks after the first doses, as opposed to the recommended 4 week.
Dizziness; nausea; full body itch/itchy red arm; itchy red arm; Swollen/painful lymph node; Swollen/painful lymph node; Fever; This is a spontaneous report received from a non-contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 55 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in arm right, administration date 12Apr2021 09:00 (Lot number: EW0158) at the age of 55 years as dose 2, single and administered in arm left, administration date 22Oct2021 16:00 (Lot number: FF9941) as dose 3 (booster), single for covid-19 immunisation. Relevant medical history included: "allergy" (unspecified if ongoing), notes: known allergies: Yes, many. Concomitant medication(s) included: SINGULAIR; ZYRTEC; CLARITIN; BENADRYL; PREVACID. Vaccination history included: Bnt162b2 (Dose Number: 1, Batch/Lot No: EP6955, Location of injection: Arm Left, Vaccine Administration Time: 09:00 AM), administration date: 22Mar2021, when the patient was 55 years old, for COVID-19 immunization. The following information was reported: DIZZINESS (non-serious) with onset 2021, outcome "recovering", described as "Dizziness"; NAUSEA (non-serious) with onset 2021, outcome "recovering", described as "nausea"; PRURITUS (non-serious) with onset 2021, outcome "recovering", described as "full body itch/itchy red arm"; ERYTHEMA (non-serious) with onset 2021, outcome "recovering", described as "itchy red arm"; LYMPHADENOPATHY (non-serious), LYMPH NODE PAIN (non-serious) all with onset 2021, outcome "recovering" and all described as "Swollen/painful lymph node"; PYREXIA (non-serious) with onset 2021, outcome "recovering", described as "Fever". Therapeutic measures were not taken as a result of dizziness, nausea, pruritus, erythema, lymphadenopathy, lymph node pain, pyrexia.  Additional Information: The patient did not taken other vaccine in four weeks and taken Other medications in two weeks was singulair, Zyrtec, Claritin, Benadryl, Prevacid. After 2nd and 3rd shots (not the first) she experienced Dizziness, nausea, full body itch, itchy red arm,  Swollen/painful lymph node and  Fever especially after 2nd shot. The patient did not have covid prior vaccination and not tested covid post vaccination. She had many know allergies.  No follow-up attempts are possible. No further information is expected.
Information was received from a physician concerning a 24 month old twin male with no known drug allergies or medical history, who was vaccinated IM on 21-MAR-2007 with a 0.5mL dose of hepatitis A virus vaccine inactivated (lot number 653619/0144F). There was no concomitant medication. It was reported that the same day he was vaccinated he developed a fever of 103 F. The physician prescribed MOTRIN and the fever resolved in 2-3 days without complications. The patient was examined on 28-MAR-2007 and had fully recovered. No product quality complaint was involved. The patient's twin sibling had a similar experience after therapy with hepatitis A virus vaccine inactivated WAES # 0705USA00137. Additional information has been requested.
Peds Pfizer vax given without diluting. Pt waited 15 min for monitoring with no reactions or symptoms of concern. Discharged with mother.
This clinical study case (initial receipt 02-Oct-2014) concerns a 7 year old male subject. At the time of the event, the subject had concomitant disease attention deficit/hyperactivity disorder and asthma. Concomitant medications included dexmethylphenidate hydrochloride for attention deficit/hyperactivity disorder, and montelukast and albuterol for asthma. The subject last received influenza vaccination in Oct-2013. The subject had received > 2 seasonal influenza vaccination since Jul-2010. On 23-Sep-2014 at 17:44, the subject received study vaccine (CSL TIV or comparator QIV, batch 0690) 0.5 ml in the left deltoid via the intramuscular route. On day 1 the patient did not have any symptoms of tonsillitis. On 24-Sep-2014, the patient developed moderate viral syndrome. On 24-Sep-2014 to 27-Sep-2014, the subject received oral paracetamol 80 mg, 4 times a day for treatment of viral syndrome, headache and malaise. On 24-Sep-2014 to 27-Sep-2014 the patient also received oral ibuprofen 80 mg, 4 times a day, for the treatment of viral syndrome, temperature and headache. On 25-Sep-2014, the subject experienced severe febrile delirium. He had a temperature of 101.6 with confusion upon awaking, characterized by inability to completely wake up. The subject had confused speech and was lethargic that persisted for 30-45 minutes. The parents stated the subject was very hard to wake up and was not making (sic) since when speaking. Parent stated that the child seemed like they were not fully awake. This lasted for about 30-45 minutes and then the child was fine. On 26-Sep-2014, the subject was seen in the emergency room and viral tonsillitis was confirmed. Throat cultures were obtained and were negative for strep. No antibiotics given. The subject received oral acetaminophen at 285 mg once for the treatment of viral syndrome, intravenous normal saline at 20 ml/kg once for treatment of dehydration and intravenous ondansetron at 4 mg once for the treatment of nausea. On 28-Sep-2014, the subject received oral paracetamol 80 mg, 4 times per day and oral ibuprofen 80 mg, 4 times per day for the treatment of viral syndrome, temperature and malaise. The outcome for febrile delirium recovered on 25-Sep-2014. Action taken in response to this adverse event was concomitant medication. No nasal viral respiratory PCR (Polymerase Chain Reaction) was done. The outcome was viral syndrome recovered on 28-Sep-2014. Action taken in response to this adverse event was medication advice sought and concomitant medication. Investigator's assessment: The investigator assessed the event of 'Febrile delirium' as serious due medically important event. The event was assessed as severe and related to study vaccine. The event 'viral syndrome' was assessed as non-serious and not related to study vaccine. Follow up (17-Feb-2015) Tests completed (PCR not done). Follow-up (23-Feb-2015) Study vaccine unblinded. Case correction (04-Mar-2015) Case upgraded to unlisted.
Information has been received from a medical assistant concerning a 12 year old female patient with no pertinent medical history and no drug reactions or allergies reported, who on 25-JUN-2010 was vaccinated with her first dose of GARDASIL (Lot #: 666118/1539Y, Exp: March-2013), 0.5ml, intramuscularly.  Concomitant medications administered on 25-JUN-2010 included: ADACEL, MENACTRA.  Secondary suspect include VARIVAX (Merck) (lot # not reported).  The medical assistant reported that after receiving the GARDASIL, the patient had a "fainting spell" where the patient turned stiff, convulsed and experienced facial paralysis which lasted for 5 seconds.  Medical assistant reported that the entire event lasted 7 seconds, and the patient's vital signs were stable.  Medical assistant reported that the patient "was a little clammy" following the "fainting spell" and stayed in the physician's office for 30 minutes after the events, so that she could be observed, and she completely recovered.  On 27-AUG-2010, the patient received the second dose of GARDASIL (Lot#: 666929/0331Z, Exp: 05-APR-2013), 0.5 ml, intramuscularly, and fainted for 3 seconds, but the patient had no facial paralysis.  Medical assistant reported that the patient experienced "a little stiffness", but she did not experience convulsions following the second dose of GARDASIL.  Unspecified treatment was given for the events.  No laboratory diagnostic studies were performed.  Medical assistant reported that the patient completely recovered from this experience.  On 06-APR-2011, the patient received her third dose of GARDASIL (Lot #: 668229/1569Z) (dose and route not reported), with no other vaccines and with no problems.  Upon internal review convulsion and facial paralysis were considered to be other important medical events.  Additional information has been requested.
I got what was diagnosed as gout in my right foot extremely bad. My diet was immaculate and I had never had goat before in my life.
Myalgia, Fever, Rash & UrticariaPruritus Narrative:  Other Relevant History:
5 doses administered more than 12 hours after 1st puncture of the vials; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (5 doses administered more than 12 hours after 1st puncture of the vials) in a 75-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 007C21A) for COVID-19 vaccination.     No Medical History information was reported.    On 09-Sep-2021 at 4:30 PM, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 09-Sep-2021 at 4:30 PM, the patient experienced EXPIRED PRODUCT ADMINISTERED (5 doses administered more than 12 hours after 1st puncture of the vials). On 09-Sep-2021 at 4:30 PM, EXPIRED PRODUCT ADMINISTERED (5 doses administered more than 12 hours after 1st puncture of the vials) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Date the vial was initially stored in the refrigerator was 02-Sep-2021. Date and time the vial was first punctured was 08-Sep-2021 at 11:43 am. The vial was stored in fridge post puncture. The vial has not undergone any temperature excursions. The total amount of time the vial was exposed to room temperature range was 35 minutes. No concomitant medications were reported. No treatment medications were reported
On day 5 after ProQuad administration patient developed pea-size left inguinal adenopathy, no fever, no pain.
After less than a day pt began to feel sick. Lymph nodes are swollen. Not feeling nausea. Irritation at site of injection, pt can tell it was from pneumo and not flu shot.
disorientation Narrative: Patient experience confusion and disorientation on day 2 of 2nd vaccination that has now resolved on day 4. Of note, he was also COVID + over the summer.
Pt receive Pneumovax 3 days ago, Pt said (R) arm got swollen, erythematous and warm. He had been taking Benadryl, (R) arm lesion measures 30 cm x 10 cm, just one lesion, warm to touch, pt said that is getting smaller.
sore in her arm  (injection site); redness from allergic reaction to bandaid; remarkable itchy allergic reaction to bandaid (latex); This spontaneous case was reported by an other health care professional and describes the occurrence of   in a 55-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 011J20A) for COVID-19 vaccination.     No Medical History information was reported.    On 30-Dec-2020, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Laboratory details was not provided.  Treatment information was not provided.  Based on the current available information and temporal association between the use of the product and the start date of the event, a causal relationship cannot be excluded.; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of the event, a causal relationship cannot be excluded.
Beginning July 2022 and continuing through October I have been sick with cold and/or flu-like symptoms during ovulation each month. Only recognized as I stopped birth control to attempt to conceive.
Inflamed; Red; Became itchy/ faint itchiness; seemed like a rash  at this point; seemed like a hives at this point; Have developed small bumps all over forearms the next day after the vaccine; This is a spontaneous report from a contactable consumer, the patient. A 18-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 09Apr2021 at 20:15 (at the age of 18-year-old) as a single dose for COVID-19 immunisation. Medical history included anemia and allergic to cats. Patient had a repeating history of anemia which was not too serious and if it gets low, she was prescribed medication. Prior to the vaccination, the patient was not diagnosed with COVID-19.Concomitant medications included vitamin d (MANUFACTURER UNKNOWN), ascorbic acid (VITAMIN C) and ferrous sulfate (IRON) all for unknown indications from an unknown date and unknown if ongoing. The patient did not receive any other medications within four weeks prior to the COVID-19 vaccine. On 10Apr2021 the next day after the vaccine, the patient experienced small bumps all over forearms . On 11Apr2021 two days after the vaccine, the small bumps became red, itchy and inflamed which seemed like a rash or hives at that point. Three days after the vaccine patient still had faint itchiness in it which had not spread nor had they gone away or showed signs of going away. Therapeutic measures were not taken as a result of the events.  The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19.The clinical outcome of the events small bumps all over forearms, red, itchy and inflamed which seemed like a rash or hives at that point and faint itchiness was not recovered at the time of this report.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Hot Flashes/headache Pt  observed for 30 mins 2 sets of vitals taken along with 02. all normal pt improved and was discharged home in a stable condition. no medications given
G47.30 SLEEP APNEA 9/13/2021 ATHEROSCLEROSIS OF AORTA G47.33 OBSTRUCTIVE SLEEP APNEA 10/7/2021 ATHEROSCLEROSIS OF AORTA J96.00 ACUTE RESPIRATORY FAILURE 10/7/2021 ATHEROSCLEROSIS OF AORTA J96.02 ACUTE HYPERCAPNIC RESPIRATORY FAILURE 10/11/2021 ATHEROSCLEROSIS OF AORTA J96.10 CHRONIC RESPIRATORY FAILURE 9/13/2021 ATHEROSCLEROSIS OF AORTA G47.30 SLEEP APNEA 9/13/2021 ATHEROSCLEROSIS OF AORTA G47.33 OBSTRUCTIVE SLEEP APNEA 10/7/2021 ATHEROSCLEROSIS OF AORTA J96.00 ACUTE RESPIRATORY FAILURE 10/7/2021 ATHEROSCLEROSIS OF AORTA J96.02 ACUTE HYPERCAPNIC RESPIRATORY FAILURE 10/11/2021 ATHEROSCLEROSIS OF AORTA J96.10 CHRONIC RESPIRATORY FAILURE 9/13/2021 ATHEROSCLEROSIS OF AORTA